期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

第二代表皮生长因子受体酪氨酸激酶抑制剂治疗非小细胞肺癌的研究进展 被引量：1

下载PDF
导出
摘要 在非小细胞肺癌的分子靶向治疗中,表皮生长因子受体是有前景的治疗靶标。吉非替尼、尔洛替尼虽已批准上市用于临床,但其治疗的临床受益率较低。现对正在研发的第二代表皮生长因子受体酪氨酸激酶抑制剂的临床试验作一综述。
作者 唐亚娟 丁振宇
机构地区 四川大学华西医院肿瘤中心 四川大学生物治疗国家重点实验室
出处 《华西药学杂志》 CAS CSCD 北大核心 2008年第5期588-589,共2页 West China Journal of Pharmaceutical Sciences
关键词 表皮生长因子受体 非小细胞肺癌 酪氨酸激酶抑制剂
分类号 R94 [医药卫生—药剂学]
  • 相关文献

参考文献20

  • 1Fukuoka M, Yano S, Giaccone G, et al. Multi - institutional randomized phase Ⅱ trial of gefitinib for previously treated patients with advanced nonsmall - cell lung cancer ( The IDEAL 1 Trial) [J]. J Clin Oncol, 2003, 21(12) :2237 - 2246.
  • 2Kris MG, Natale RB, Herbst RS,et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non - small cell lung cancer: A randomized trial [J].JAMA, 2003, 290(16) :2149 -2158.
  • 3Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non- small- cell lung cancer to gefitinib [ J ]. N Engl J Med, 2004, 350(21) :2129 -2139.
  • 4Paez JG,Janne PA,Lee JC,et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy[ J]. Science, 2004, 304(5676) :1497 - 1500.
  • 5Pao W, Miller V, Zakowski M ,et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib [ J ]. Proc Nail Acad Sci USA ,2004,101 ( 36 ) : 13306 - 13311.
  • 6温华,张贺龙,康健.选择性表皮生长因子受体酪氨酸激酶抑制剂——ZD1839对NK和LAK细胞毒作用的影响[J].中国免疫学杂志,2004,20(10):677-678. 被引量：1
  • 7Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non - small - cell lung cancer to gefitinib[ J]. N Engl J Med, 2005, 352(20) :786 -792.
  • 8Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain [ J ]. Plos Med, 2005, 2 (9) :e73.
  • 9Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network [ J]. Nat Rev Mol Cell Biol,2001,2 ( 2 ) : 127 - 137.
  • 10Erlichman C, Hidalgo M, Boni JP, et al. Phase I study of EKB - 569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors[ J]. J Clin Oncol, 2006, 24 ( 15 ) :2252 - 2260.

二级参考文献10

  • 1方敏.淋巴细胞[A].龚非力 主编.基础免疫学[C].湖北:科学技术出版社,1998.15-18.
  • 2Salomon D S,Brandt R,Ciardiello F et al.Epidermal growth factor-related peptides and their receptors in human malignances [J].Crit Rev Oncol Hematol,1995;19:183-232.
  • 3Chen X,Yeung T K,Wang Z.Enhanced drug resistance in cells coexpressing ErbB2 with EGF receptor or ErbB3 [J].Biochem Biophys Res Commun,2000;277:757-763.
  • 4Baselga J.New techonologies in epidermal growth factor receptor-targeted cancer therapy [J].Signal,2000;1:12-21.
  • 5Ciardiello F,Caputo R,Bianco R et al.Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor [J].Clin Cancer Res,2001;7:1459-1465.
  • 6Sirotnak F M,Zakowski M F,Miller V A et al.Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase [J].Clin Cancer Res,2000;6:4885-4892.
  • 7Moasser M M,Basso A,Averbuch S D et al.The tyrosine kinase inhibitor ZD1839(''Iressa'')inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells [J].Cancer Res,2001;61:7184-7188.
  • 8Ranson M,Hammond L A,Ferry D et al.ZD1839,a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor,is well tolerated and active in patients with solid,malignant tumors:results of a phase I trial [J].J Clin Oncol,2002;20:2240-2250.
  • 9Parajuli P,Nishioka Y,Nishimura N et al.Cytolysis of human dendritic cells by autologous lymphokine activated killer cells:participation of both T cells and NK cells in the killing [J].J Leukoc Biol,1999;65:764-770.
  • 10Cohen M H,Williams G A,Sridhara R et al.FDA drug approval summary:gefitinib (ZD1839) (IressaD○R) tablets [J].The Oncologist,2003;8:303-306.

同被引文献5

引证文献1

二级引证文献1

华西药学杂志
2008年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部